CG Oncology Cash Flow Statement
NASDAQ: CGONHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
63.82+0.56 (+0.89%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
CG Oncology free cash flow
In fiscal 2025, CG Oncology generated -$132.3 million of operating cash flow and spent $134,000 on capital expenditures. That left free cash flow of -$132.5 million, a free-cash-flow margin of -3279.2% of revenue.
Summary generated from market data by MetaCap's automated system. Methodology
CG Oncology cash flow statement (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 |
|---|---|---|---|
| Net Income | -161.00M | -88.04M | -48.61M |
| Net Income growth (YoY) | — | — | — |
| Depreciation & Amortization | 1.45M | 32.00K | 17.00K |
| Stock-Based Compensation | 26.68M | 11.40M | 1.53M |
| Change in Working Capital | -3.99M | 2.51M | 2.02M |
| Operating Cash Flow | -132.35M | -78.71M | -45.68M |
| Capital Expenditures | -134.00K | -234.00K | — |
| Investing Cash Flow | -245.82M | -300.76M | -121.19M |
| Financing Cash Flow | 153.59M | 628.28M | 87.00M |
| Net Change in Cash | -224.58M | 248.80M | -79.88M |
| Free Cash Flow | -132.48M | -78.95M | -45.68M |
This table shows 3 annual periods of CG Oncology's cash flow statement, from FY 2025 back to FY 2023, across 10 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow CGON's reporting calendar. What is a cash flow statement?